MedPath

Kyowa Kirin Korea Co., Ltd.

🇰🇷South Korea
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.kyowakirin.com/kr

Clinical Trials

7

Active:0
Completed:3

Trial Phases

3 Phases

Phase 1:1
Phase 2:1
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (33.3%)
Phase 2
1 (33.3%)
Phase 3
1 (33.3%)

Multicenter, Open, Prospective, 48 Weeks, Observational Study ,Evaluate the Safety and Efficacy of Nephoxil Capsule

Recruiting
Conditions
Hyperphosphatemia
Interventions
Drug: the low-dose group (1.5 g/day) or the standard-dose group (4 g/day)
First Posted Date
2024-01-16
Last Posted Date
2024-04-29
Lead Sponsor
Kyowa Kirin Korea Co., Ltd.
Target Recruit Count
100
Registration Number
NCT06206135
Locations
🇰🇷

Jesus Hospital, Jeonju, Korea, Republic of

Post Marketing Surveillance Study to Observe Safety and Effectiveness of CRYSVITA® in S. Korean Patients

Recruiting
Conditions
FGF23-related Hypophosphataemic Rickets and Osteomalacia
First Posted Date
2024-01-11
Last Posted Date
2024-04-29
Lead Sponsor
Kyowa Kirin Korea Co., Ltd.
Target Recruit Count
100
Registration Number
NCT06202027
Locations
🇰🇷

Choi Hyeokjun, Seoul, Korea, Republic of

Post Marketing Surveillance Study to Observe Safety and Effectiveness of NEPHOXIL ® in S. Korea Patients

Recruiting
Conditions
Hyperphosphatemia
First Posted Date
2024-01-02
Last Posted Date
2024-04-29
Lead Sponsor
Kyowa Kirin Korea Co., Ltd.
Target Recruit Count
600
Registration Number
NCT06186934
Locations
🇰🇷

Jesus Hospital, Jeonju, Korea, Republic of

An Observational Study to Evaluate the Safety and Efficacy of Pegfilgrastim (Neulasta®)

Completed
Conditions
Breast Cancer Female
Breast Neoplasm Female
First Posted Date
2018-02-14
Last Posted Date
2024-05-14
Lead Sponsor
Kyowa Kirin Korea Co., Ltd.
Target Recruit Count
1300
Registration Number
NCT03433560
Locations
🇰🇷

Wonju Severance Christian Hospital, Wonju, Gangwon, Korea, Republic of

🇰🇷

Bucheon Soonchunhyang University Hospital, Bucheon, Kyounggi, Korea, Republic of

🇰🇷

Pusan National University Yangsan Hospital, Yangsan, Kyoungsang, Korea, Republic of

A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea

Phase 3
Completed
Conditions
Moderate to Severe Plaque Psoriasis
Interventions
Drug: Placebo
First Posted Date
2016-12-05
Last Posted Date
2024-04-29
Lead Sponsor
Kyowa Kirin Korea Co., Ltd.
Target Recruit Count
62
Registration Number
NCT02982005
Locations
🇰🇷

Korea, Republic of, Seoul, Korea, Republic of

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.